ABVC BIOPHARMA, INC. — 2018 Form 10-K Summary
Entity and period: The supplied filing is for American BriVision (Holding) Corporation, for the fiscal year ended December 31, 2018. The company describes itself as an early-stage biotechnology business developing drugs and a medical device, alongside pharmaceutical development and manufacturing services through subsidiaries. It reported no operating revenue. The filing says the fiscal year changed from a September 30 year-end to a December 31 year-end, and describes 2017 as a three-month transition period in one section; elsewhere, it presents 2017 comparative results as a full year. Comparability of the reported periods is therefore unclear from the filing text.
Key financial results and liquidity
| Metric | 2018 | 2017 as presented |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1.394 million | $4.139 million |
| Research and development expense | $669,668 | $3.172 million |
| Operating loss | $1.394 million | $4.139 million |
| Net loss | $4.101 million | $4.243 million |
| Net loss per share, basic and diluted | $0.02 | $0.02 |
| Cash used in operating activities | $630,195 | $1.485 million |
| Cash provided by financing activities | $593,000 | $1.560 million |
With no revenue or cost of revenue, gross profit and gross margin were not meaningful. The net loss narrowed by about 3.3% year over year as presented, despite a $2.549 million impairment loss on the Rgene equity investment. The lower R&D expense was the primary stated reason for reduced operating expenses.
- Year-end liquidity: Current assets were $96,273, including $40,044 cash and $16,093 restricted cash; current liabilities were $5.568 million, producing a $5.472 million working-capital deficit. Total liabilities were $5.846 million; stockholders’ deficit was $5.749 million.
- Obligations: Convertible notes totaled $800,000 principal at year-end, bearing 8% interest, with $27,467 accrued interest. The notes are unsecured and include conversion terms tied to potential equity offerings. Amounts due to related parties totaled $4.463 million, including a $3.0 million unpaid BioFirst collaboration obligation and related-party advances and loans.
- Cash flow: The company reported a $37,195 net decrease in cash and cash equivalents for 2018. The cash-flow statement’s ending balance of $56,137 includes restricted cash; the balance sheet separately reports cash and restricted cash.
Changes, outlook, risks and unusual items
- Rgene impairment: The company wrote off its Rgene investment and recorded a $2.549 million impairment charge, citing Rgene’s operating performance and adverse market conditions. The filing says planned projects would continue to be managed and supported.
- Development pipeline: The company reported six drug candidates and one medical device under development, largely licensed from related parties. ABV-1504’s Phase II patient study was completed, with data lock and analysis still underway; the filing reported no serious adverse events in that study. Other planned clinical work—including ABV-1505 and ABV-1702/1703 studies—was subject to financing, site, or other conditions. ABV-1701 completed a 10-patient Phase I study in Australia; preparation of its final study report and planning for a pivotal study remained outstanding.
- Going concern and funding: Management said it did not believe available funds were sufficient for the next 12 months and that continued operations depend on obtaining financing and eventually achieving profitable operations. The auditor’s report highlights substantial doubt about the company’s ability to continue as a going concern. Management proposed equity sales and borrowings but gave no assurance of success.
- Subsequent events: The BioLite and BioKey mergers closed on February 8, 2019, after year-end, with consideration primarily in ABVC shares. A January 2019 Cathay Bank facility provided a $1.0 million revolving line; the company reported drawing $500,000. The borrowing is secured by nearly all assets of the company and BriVision, with individual guarantees described in the filing.
- Governance and controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end, citing limited monitoring and lack of segregation of duties due to a one-person financial staff. The auditor did not provide an internal-control attestation. The financial-statement audit opinion was unqualified and included a going-concern emphasis.
- Related-party exposure: Several licensing, financing, and collaboration arrangements involve related parties. The filing also describes a BioLite license agreement with potential payments totaling up to $100 million, tied to milestones, as well as the unpaid BioFirst obligation.
Most important facts for investors to verify
- Confirm the correct legal issuer and filing entity, and resolve the filing’s inconsistent presentation of the 2017 comparison period.
- Review current cash, restricted cash, near-term obligations, related-party balances, and the status and terms of financing after year-end.
- Verify the status of the $1.0 million Cathay Bank line, the $500,000 draw, collateral, guarantees, and repayment requirements.
- Assess whether the company can fund its clinical pipeline and meet the BioFirst and other contractual commitments, including milestone-based payments.
- Check progress and independently reported results for clinical trials, regulatory applications, and the ABV-1701 pivotal-study plan; distinguish planned milestones from completed outcomes.
- Review the Rgene impairment basis and any subsequent developments affecting the investment or co-development projects.
- Monitor remediation of ineffective financial reporting controls and the effects of the BioLite/BioKey merger, including actual post-merger share issuance and dilution.